Pain Management News and Research

RSS

NAPRELAN Dose Card launched by Victory Pharma

Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise.

23 Nov 2009

RBC Life Sciences reports net sales of $6.49M for third-quarter 2009

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, reported today company-wide net sales of $6.49 million for the quarter ended September 30, 2009, compared to net sales of $9.93 million for the same quarter last year.

20 Nov 2009

Low-level laser therapy increases tumour growth in skin cancer

High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Researchers writing in the open access journal BMC Cancer studied the pain relieving, anti-inflammatory 'cold laser', finding that it caused increased tumour growth in a mouse model of skin cancer.

19 Nov 2009

Six new degree programs to be offered by High-Tech Institute in Minneapolis

High-Tech Institute in Minneapolis will begin offering six new degree programs, with a class start set for January 11, 2010 for all programs. The school is located at 5100 Gamble Drive, Suite 200 in St. Louis Park, Minn.

19 Nov 2009

FDA approves NeurogesX's Qutenza patch for postherpetic neuralgia treatment

NeurogesX, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia (PHN), the nerve pain which can follow shingles.

17 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2009.

16 Nov 2009

Spine Care Institute established by Hospital for Special Surgery

Hospital for Special Surgery today announced the establishment of one of the most comprehensive centers of excellence in the country for the treatment of all nonoperative and operative spine disorders.

16 Nov 2009

Zynex signs lease to rent a 75,000-square-foot building

Zynex, Inc., a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces it has signed a lease to rent a 75,000-square-foot building in Lone Tree (Littleton), Colorado. Zynex currently leases 16,553 square feet in Littleton, Colorado and the new building will house its headquarters, office, plant and warehouse.

13 Nov 2009

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

13 Nov 2009

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today the company’s development and validation of a clinical quantitative assay for the new drug tapentadol (Nucynta™) by liquid chromatography/tandem mass spectrometry (LC-MS/MS).

12 Nov 2009

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the European Union, Turkey, Switzerland, Norway, the Balkan countries and Iceland. Terms of the agreement were not disclosed. Cerimon initially acquired the U.S. rights to develop and commercialize the patch formulation of diclofenac in 2005.

10 Nov 2009

National Pain Summit calls for better pain care in America

Pain medicine physicians from the American Academy of Pain Medicine (AAPM) continued to advance the call for better pain care as they joined with physician leaders from across the country in a closed-door National Pain Summit that took place adjacent to an AMA meeting last week in Houston, Texas.

10 Nov 2009

Cannabinoid medicine: Challenges for health care providers and its potential benefits for patients

Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.

10 Nov 2009

Meditation training can have a positive effect on pain management

A new study examining the perception of pain and the effects of various mental training techniques has found that relatively short and simple mindfulness meditation training can have a significant positive effect on pain management.

10 Nov 2009

Military personnel with back pain unlikely to return to duty after treatment

Military personnel evacuated out of Iraq and Afghanistan because of back pain are unlikely to return to the line of duty regardless of the treatment they receive, according to research led by a Johns Hopkins pain management specialist.

9 Nov 2009

Pain management physician offers house calls to residents of Manhattan in New York City

Davis Bregman, a pain management physician will now offer routine house calls to residents of Manhattan in New York City. Patients will be able to request a house call by calling the office at 212-918-1629 or sending an email from davisbregman.com.

9 Nov 2009

FDA approves the New Drug Application for Pennsaid Topical Solution

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009